Our approach

We extend our portfolio companies’ capabilities and focus their development

Our approach

We invest in medical and healthcare innovations which are based on sound, novel science and have high potential to positively impact patients.

Sound, novel science

We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena.

High healthcare impact potential

Only innovations that can address an unmet medical need in a significant way are being considered for investment. We aspire to invest in solutions that provide substantial healthcare impact.

Extending Capabilities

Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies.

Focused development

We guide our investees along their journey from the scientific discovery to a targeted product development track. Together with the founders we shape the company and define the objectives to enable a successful exit.

Acerta Pharma: Accelerate a novel concept in leukemia

Case 1

Inception

Following the closing of MSD’s (originally Organon) R&D facilities in Oss, the Netherlands, a number of immunology programs were terminated.
Allard Kaptein and Tjeerd Barf (ex MSD), together with Edward van Wezel (BGV’s managing partner) planned to redirect a promising program into immuno-oncology (leukemia) and take it forward.

Creating value

Within one year from inception, Acerta Pharma entered into clinical trials and presented compelling clinical results by the end of 2015. AstraZeneca acquired a 55% stake in the Company in a deal with an overall value over $7 billion. The lead compound, acalabrutinib, is currently being tested in late stage clinical trials.

BGV’s involvement

Edward co-founded Acerta Pharma and served on its board until its trade-sale to AstraZeneca. He led the licensing negotiations with MSD and provided the seed capital. He also brought a very experienced team into the company from the outset, which led to leading US-based venture capital groups to invest into the company.

Dezima Pharma: Build a virtual organization around a promising cardiovascular asset

Case 2

Inception

John Kastelein, a leading physician in the cardiovascular field and advisor to BGV identified a promising novel compound for the management of cholesterol.

Together with its partner, Forbion Capital Partners, BGV planned to create a new company to develop the drug and provided the seed financing.

Creating value

After two years the Dezima team concluded the TULIP study, demonstrating the positive impact of the drug on cholesterol.  Within two months of publishing the data, the company was acquired by Amgen for a value up to $ 1.55 billion.

BGV’s involvement

The BGV and Forbion teams set up the new company, Dezima Pharma, with Rob de Ree, currently operating partner at BGV, as its CEO and with BGV on the board. They built a network of experts which operated the Company as a virtual organisation.